Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer via a Multi-omics Integrative Analysis.

Song X, Ji J, Gleason KJ, Yang F, Martignetti JA, Chen LS, Wang P.

Mol Cell Proteomics. 2019 Aug 9;18(8 suppl 1):S52-S65. doi: 10.1074/mcp.RA118.001220. Epub 2019 Jun 21.

2.

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid.

Dragulska SA, Wlodarczyk MT, Poursharifi M, Martignetti JA, Mieszawska AJ.

J Vis Exp. 2019 Feb 27;(144). doi: 10.3791/59034.

PMID:
30882795
3.

Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy.

Martignetti JA, Pandya D, Nagarsheth N, Chen Y, Camacho O, Tomita S, Brodman M, Ascher-Walsh C, Kolev V, Cohen S, Harkins TT, Schadt EE, Reva B, Sebra R, Dottino P.

Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). pii: a003269. doi: 10.1101/mcs.a003269. Print 2018 Dec.

4.

Protein-losing enteropathy and joint contractures caused by a novel homozygous ANTXR2 mutation.

Schussler E, Linkner RV, Levitt J, Mehta L, Martignetti JA, Oishi K.

Adv Genomics Genet. 2018;8:17-21. doi: 10.2147/AGG.S159077. Epub 2018 Jun 27.

5.

Tripeptide-Stabilized Oil-in-Water Nanoemulsion of an Oleic Acids-Platinum(II) Conjugate as an Anticancer Nanomedicine.

Dragulska SA, Chen Y, Wlodarczyk MT, Poursharifi M, Dottino P, Ulijn RV, Martignetti JA, Mieszawska AJ.

Bioconjug Chem. 2018 Aug 15;29(8):2514-2519. doi: 10.1021/acs.bioconjchem.8b00409. Epub 2018 Jul 16.

6.

Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look".

Schwartz M, Camacho-Vanegas O, Wood AM, Dashkoff M, Whitelock C, Harkins TT, Cohen CJ, Beddoe AM, Dottino P, Martignetti JA.

Int J Gynecol Cancer. 2018 Mar;28(3):479-485. doi: 10.1097/IGC.0000000000001190.

7.

Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.

Nair N, Camacho-Vanegas O, Rykunov D, Dashkoff M, Camacho SC, Schumacher CA, Irish JC, Harkins TT, Freeman E, Garcia I, Pereira E, Kendall S, Belfer R, Kalir T, Sebra R, Reva B, Dottino P, Martignetti JA.

PLoS Med. 2016 Dec 27;13(12):e1002206. doi: 10.1371/journal.pmed.1002206. eCollection 2016 Dec.

8.

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.

Chen Y, Camacho SC, Silvers TR, Razak AR, Gabrail NY, Gerecitano JF, Kalir E, Pereira E, Evans BR, Ramus SJ, Huang F, Priedigkeit N, Rodriguez E, Donovan M, Khan F, Kalir T, Sebra R, Uzilov A, Chen R, Sinha R, Halpert R, Billaud JN, Shacham S, McCauley D, Landesman Y, Rashal T, Kauffman M, Mirza MR, Mau-Sørensen M, Dottino P, Martignetti JA.

Clin Cancer Res. 2017 Mar 15;23(6):1552-1563. doi: 10.1158/1078-0432.CCR-16-1333. Epub 2016 Sep 20.

9.

Porokeratotic Adnexal Ostial Nevus-Report of a Case With Unusual Clinical and Histologic Features.

Lanoue J, Jacobson KB, Ooka K, Singh C, Camacho-Vanegas O, Martignetti JA, Levitt J, Phelps RG.

Skinmed. 2016 Jun 1;14(3):221-4. eCollection 2016.

PMID:
27502264
10.

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.

Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, Nair N, Moshier E, Wooten M, Uzilov A, Chen R, Prasad-Hayes M, Zakashansky K, Beddoe AM, Schadt E, Dottino P, Martignetti JA.

PLoS One. 2015 Dec 30;10(12):e0145754. doi: 10.1371/journal.pone.0145754. eCollection 2015.

11.

The impact of simvastatin on pulmonary effectors of Pseudomonas aeruginosa infection.

Hennessy E, O'Callaghan J, Mooij MJ, Legendre C, Camacho-Vanegas O, Camacho SC, Adams C, Martignetti JA, O'Gara F.

PLoS One. 2014 Jul 10;9(7):e102200. doi: 10.1371/journal.pone.0102200. eCollection 2014.

12.

Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.

Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA.

Gynecol Oncol. 2014 Sep;134(3):591-8. doi: 10.1016/j.ygyno.2014.06.025. Epub 2014 Jul 1.

PMID:
24995581
13.

STK11 domain XI mutations: candidate genetic drivers leading to the development of dysplastic polyps in Peutz-Jeghers syndrome.

Wang Z, Wu B, Mosig RA, Chen Y, Ye F, Zhang Y, Gong W, Gong L, Huang F, Wang X, Nie B, Zheng H, Cui M, Wang Y, Wang J, Chen C, Polydorides AD, Zhang DY, Martignetti JA, Jiang B.

Hum Mutat. 2014 Jul;35(7):851-8. doi: 10.1002/humu.22549. Epub 2014 Jun 3.

PMID:
24652667
14.

Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA.

Martignetti JA, Camacho-Vanegas O, Priedigkeit N, Camacho C, Pereira E, Lin L, Garnar-Wortzel L, Miller D, Losic B, Shah H, Liao J, Ma J, Lahiri P, Chee M, Schadt E, Dottino P.

Neoplasia. 2014 Jan;16(1):97-103.

15.

Morbid obesity resulting from inactivation of the ciliary protein CEP19 in humans and mice.

Shalata A, Ramirez MC, Desnick RJ, Priedigkeit N, Buettner C, Lindtner C, Mahroum M, Abdul-Ghani M, Dong F, Arar N, Camacho-Vanegas O, Zhang R, Camacho SC, Chen Y, Ibdah M, DeFronzo R, Gillespie V, Kelley K, Dynlacht BD, Kim S, Glucksman MJ, Borochowitz ZU, Martignetti JA.

Am J Hum Genet. 2013 Dec 5;93(6):1061-71. doi: 10.1016/j.ajhg.2013.10.025. Epub 2013 Nov 21.

16.

First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia.

Favier R, Feriel J, Favier M, Denoyelle F, Martignetti JA.

Pediatrics. 2013 Sep;132(3):e793-5. doi: 10.1542/peds.2012-3807. Epub 2013 Aug 12.

PMID:
23940247
17.

Multicentric osteolysis with nodulosis and arthropathy (MONA) with cardiac malformation, mimicking polyarticular juvenile idiopathic arthritis: case report and literature review.

Castberg FC, Kjaergaard S, Mosig RA, Lobl M, Martignetti C, Martignetti JA, Myrup C, Zak M.

Eur J Pediatr. 2013 Dec;172(12):1657-63. doi: 10.1007/s00431-013-2102-8. Epub 2013 Jul 31. Review.

PMID:
23900523
18.

Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis.

Martignetti JA, Tian L, Li D, Ramirez MC, Camacho-Vanegas O, Camacho SC, Guo Y, Zand DJ, Bernstein AM, Masur SK, Kim CE, Otieno FG, Hou C, Abdel-Magid N, Tweddale B, Metry D, Fournet JC, Papp E, McPherson EW, Zabel C, Vaksmann G, Morisot C, Keating B, Sleiman PM, Cleveland JA, Everman DB, Zackai E, Hakonarson H.

Am J Hum Genet. 2013 Jun 6;92(6):1001-7. doi: 10.1016/j.ajhg.2013.04.024. Epub 2013 May 23.

19.

Shaking the family tree: identification of novel and biologically active alternatively spliced isoforms across the KLF family of transcription factors.

Camacho-Vanegas O, Till J, Miranda-Lorenzo I, Ozturk B, Camacho SC, Martignetti JA.

FASEB J. 2013 Feb;27(2):432-6. doi: 10.1096/fj.12-220319. Epub 2012 Nov 7.

PMID:
23134681
20.

Mutation of membrane type-1 metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome.

Evans BR, Mosig RA, Lobl M, Martignetti CR, Camacho C, Grum-Tokars V, Glucksman MJ, Martignetti JA.

Am J Hum Genet. 2012 Sep 7;91(3):572-6. doi: 10.1016/j.ajhg.2012.07.022. Epub 2012 Aug 23.

21.

Loss of MMP-2 in murine osteoblasts upregulates osteopontin and bone sialoprotein expression in a circuit regulating bone homeostasis.

Mosig RA, Martignetti JA.

Dis Model Mech. 2013 Mar;6(2):397-403. doi: 10.1242/dmm.007914. Epub 2012 Aug 23.

22.

A new feature of the MYH9-related syndrome: chronic transaminase elevation.

Favier R, DiFeo A, Hezard N, Fabre M, Bedossa P, Martignetti JA.

Hepatology. 2013 Mar;57(3):1288-9. doi: 10.1002/hep.25913. Epub 2012 Nov 27. No abstract available.

PMID:
22806255
23.

Primate genome gain and loss: a bone dysplasia, muscular dystrophy, and bone cancer syndrome resulting from mutated retroviral-derived MTAP transcripts.

Camacho-Vanegas O, Camacho SC, Till J, Miranda-Lorenzo I, Terzo E, Ramirez MC, Schramm V, Cordovano G, Watts G, Mehta S, Kimonis V, Hoch B, Philibert KD, Raabe CA, Bishop DF, Glucksman MJ, Martignetti JA.

Am J Hum Genet. 2012 Apr 6;90(4):614-27. doi: 10.1016/j.ajhg.2012.02.024. Epub 2012 Mar 29.

24.

Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene.

Calderon MR, Verway M, An BS, DiFeo A, Bismar TA, Ann DK, Martignetti JA, Shalom-Barak T, White JH.

J Biol Chem. 2012 Mar 16;287(12):8662-74. doi: 10.1074/jbc.M111.311605. Epub 2012 Jan 25.

25.

Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer.

Mosig RA, Lin L, Senturk E, Shah H, Huang F, Schlosshauer P, Cohen S, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P, Martignetti JA.

J Ovarian Res. 2012 Jan 24;5:4. doi: 10.1186/1757-2215-5-4.

26.

IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer.

Mosig RA, Lobl M, Senturk E, Shah H, Cohen S, Chudin E, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P, Martignetti JA.

J Ovarian Res. 2012 Jan 20;5(1):3. doi: 10.1186/1757-2215-5-3.

27.

Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity.

Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, Bussel JB, Favier R, Orange JS.

Blood. 2011 Nov 24;118(22):5862-71. doi: 10.1182/blood-2011-03-344846.

28.

Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression.

Agnani D, Camacho-Vanegas O, Camacho C, Lele S, Odunsi K, Cohen S, Dottino P, Martignetti JA.

J Ovarian Res. 2011 Oct 22;4:18. doi: 10.1186/1757-2215-4-18.

29.

Hyaline fibromatosis syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.

Deuquet J, Lausch E, Guex N, Abrami L, Salvi S, Lakkaraju A, Ramirez MC, Martignetti JA, Rokicki D, Bonafe L, Superti-Furga A, van der Goot FG.

EMBO Mol Med. 2011 Apr;3(4):208-21. doi: 10.1002/emmm.201100124. Epub 2011 Feb 15.

30.

The first report of homozygous May-Hegglin anomaly E1841K mutation.

Poopak B, Rezvani H, Difeo A, Martignetti JA, Khosravipour G, Yousefian A, Farahani K, Haghnejad Doshanlo F, Saki N.

Eur J Haematol. 2011 Apr;86(4):357. doi: 10.1111/j.1600-0609.2010.01553.x. Epub 2011 Jan 11. No abstract available.

PMID:
21083612
31.

Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function.

Rodríguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA.

PLoS One. 2010 Sep 9;5(9). pii: e12639. doi: 10.1371/journal.pone.0012639.

32.

A critical re-appraisal of BRCA1 methylation studies in ovarian cancer.

Senturk E, Cohen S, Dottino PR, Martignetti JA.

Gynecol Oncol. 2010 Nov;119(2):376-83. doi: 10.1016/j.ygyno.2010.07.026. Epub 2010 Aug 24. Review.

PMID:
20797776
33.

Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression.

Radbill BD, Gupta R, Ramirez MC, DiFeo A, Martignetti JA, Alvarez CE, Friedman SL, Narla G, Vrabie R, Bowles R, Saiman Y, Bansal MB.

Dig Dis Sci. 2011 Feb;56(2):406-16. doi: 10.1007/s10620-010-1296-0. Epub 2010 Jun 19.

34.

Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.

DiFeo A, Narla G, Martignetti JA.

Mt Sinai J Med. 2009 Dec;76(6):557-66. doi: 10.1002/msj.20150. Review.

35.

The Krüppel traffic report: cooperative signals direct KLF8 nuclear transport.

Rodríguez E, Martignetti JA.

Cell Res. 2009 Sep;19(9):1041-3. doi: 10.1038/cr.2009.103. Epub 2009 Sep 3. No abstract available.

36.

Myosin IIA associates with NK cell lytic granules to enable their interaction with F-actin and function at the immunological synapse.

Sanborn KB, Rak GD, Maru SY, Demers K, Difeo A, Martignetti JA, Betts MR, Favier R, Banerjee PP, Orange JS.

J Immunol. 2009 Jun 1;182(11):6969-84. doi: 10.4049/jimmunol.0804337.

37.

KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.

Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA.

Cancer Res. 2009 Jun 1;69(11):4733-41. doi: 10.1158/0008-5472.CAN-08-4282. Epub 2009 May 12.

38.

Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum.

Deuquet J, Abrami L, Difeo A, Ramirez MC, Martignetti JA, van der Goot FG.

Hum Mutat. 2009 Apr;30(4):583-9. doi: 10.1002/humu.20872.

PMID:
19191226
39.

Functional role of the KLF6 tumour suppressor gene in gastric cancer.

Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G.

Eur J Cancer. 2009 Mar;45(4):666-76. doi: 10.1016/j.ejca.2008.11.009. Epub 2008 Dec 26.

40.

The role of KLF6 and its splice variants in cancer therapy.

DiFeo A, Martignetti JA, Narla G.

Drug Resist Updat. 2009 Feb-Apr;12(1-2):1-7. doi: 10.1016/j.drup.2008.11.001. Epub 2008 Dec 18. Review.

PMID:
19097929
41.

A novel matrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects.

Tuysuz B, Mosig R, Altun G, Sancak S, Glucksman MJ, Martignetti JA.

Eur J Hum Genet. 2009 May;17(5):565-72. doi: 10.1038/ejhg.2008.204. Epub 2008 Nov 5.

42.

Pivotal role of mTOR signaling in hepatocellular carcinoma.

Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM.

Gastroenterology. 2008 Dec;135(6):1972-83, 1983.e1-11. doi: 10.1053/j.gastro.2008.08.008. Epub 2008 Aug 20.

43.

Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer.

Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, Friess H, Friedman SL.

Eur J Cancer. 2008 Sep;44(13):1895-903. doi: 10.1016/j.ejca.2008.06.030. Epub 2008 Aug 6.

44.

Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers.

Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM.

J Hepatol. 2008 Oct;49(4):581-8. doi: 10.1016/j.jhep.2008.03.032. Epub 2008 May 20.

45.

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA.

J Clin Invest. 2008 Aug;118(8):2711-21. doi: 10.1172/JCI34780.

46.

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL.

Gastroenterology. 2008 May;134(5):1521-31. doi: 10.1053/j.gastro.2008.02.015. Epub 2008 Feb 13. Erratum in: Gastroenterology. 2008 Jul;135(1):326.

47.

A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.

DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, Narla G.

Cancer Res. 2008 Feb 15;68(4):965-70. doi: 10.1158/0008-5472.CAN-07-2604. Epub 2008 Feb 4.

48.

Infantile systemic hyalinosis: Case report and review of the literature.

Lindvall LE, Kormeili T, Chen E, Ramirez MC, Grum-Tokars V, Glucksman MJ, Martignetti JA, Zaragoza MV, Dyson SW.

J Am Acad Dermatol. 2008 Feb;58(2):303-7. doi: 10.1016/j.jaad.2007.06.008. Review.

PMID:
18222328
49.

KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma.

Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, Kalir T, Friedman SL, Schlecht NF, Genden EM, Urken M, Brandwein-Gensler M, Martignetti JA.

Int J Cancer. 2007 Nov 1;121(9):1976-83.

50.

Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma.

Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA.

Int J Cancer. 2007 Sep 15;121(6):1390-5.

Supplemental Content

Loading ...
Support Center